Veracyte (NASDAQ:VCYT) vs. Wesana Health (OTCMKTS:WSNAF) Head-To-Head Contrast

Wesana Health (OTCMKTS:WSNAF) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Profitability

This table compares Wesana Health and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Wesana Health	N/A	N/A	N/A
Veracyte	20.37%	9.26%	8.61%

Analyst Ratings

This is a summary of current ratings for Wesana Health and Veracyte, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Wesana Health	0	0	0	0	0.00
Veracyte	1	2	6	2	2.82

Veracyte has a consensus target price of $54.33, suggesting a potential upside of 31.02%. Given Veracyte’s stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Wesana Health.

Earnings & Valuation

This table compares Wesana Health and Veracyte”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Wesana Health	N/A	N/A	N/A	N/A	N/A
Veracyte	$517.15 million	6.45	$66.35 million	$1.41	29.41

Veracyte has higher revenue and earnings than Wesana Health.

Summary

Veracyte beats Wesana Health on 8 of the 8 factors compared between the two stocks.

About Wesana Health

Wesana Health Holdings Inc. does not have significant operations. Previously, it was developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological, and mental health ailments caused by trauma. The company is headquartered in Chicago, Illinois.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.